scanX
Laurus Labs

Laurus Labs

979.80
-3.35
(-0.34%)
hide
Key Fundamentals
Add Ratio
Market Cap
52,892.00 Cr
EPS
6.65
PE Ratio
77.51
Dividend Yield
0.12 %
Industry
Healthcare
52 Week High
994.80
52 Week Low
474.05
PB Ratio
11.00
Debt to Equity
0.62
Sector
Pharmaceuticals
Analyst Rating and Forecast
- By Refinitiv from13 analysts
SELL
Analysts have suggested that investors can sell this stock
Buy
Buy+38.46 %
+38.46 %
Hold
Hold+15.38 %
+15.38 %
Sell
Sell+46.15 %
+46.15 %
Forecast For
Actual

Company News

View All News
Caret
positive
Laurus Labs Reports Strong Q2 FY26 Results with 35% Revenue Growth and Margin Expansion9 days ago
Laurus Labs delivered robust quarterly results with revenue of INR 1,653 crores, marking 35% growth. The company achieved gross margins of approximately 60% and EBITDA margins of 26%, representing an 11 percentage point expansion. ARV business contributed INR 733 crores compared to INR 647 crores in the previous quarter. CDMO division recorded sales of INR 471 crores for the quarter and INR 964 crores for the first half with 88% growth, driven by mid-to-late phase program deliveries and commercial supplies. The company received allotment of 532 acres from Andhra Pradesh government in Vizag, where it plans to invest $600 million over 8 years for a pharmaceutical manufacturing complex. Laurus invested $2 million in an ADC technology platform company to enhance integrated ADC services. The company maintained its ARV sales guidance of INR 2,500 crores plus or minus INR 200 crores for the full year. Total capex for the current year is estimated at INR 1,000 crores, with the company planning continued investments in new modalities including fermentation, gene therapy, and ADC capabilities.
neutral
Laurus Labs Shares Drop Despite Strong Q2 Results as Analysts Remain Divided on ValuationOct 24, 2025
Laurus Labs shares declined 0.50% to ₹929.75 despite reporting better-than-expected quarterly results. The pharmaceutical company delivered a 35.1% year-on-year revenue growth to ₹16.5 billion, with EBITDA margin expanding 980 basis points to 24.4%. The synthesis business and formulation sales both grew 58% year-on-year, with formulations reaching ₹5.2 billion. Analyst opinions are sharply divided - domestic brokerages Motilal Oswal, DAM Capital, and CIE maintained Buy ratings with target prices between ₹1,083-₹1,110, citing earnings upcycle and CDMO scale-up. However, foreign brokerages remained cautious about premium valuations, with Goldman Sachs and Kotak Securities issuing Sell ratings with targets of ₹775 and ₹625 respectively. Jefferies maintained Underperform with a ₹700 target, expressing concerns about the company's announced $600 million capex over eight years for a new Vizag site.
positive
Laurus Labs Promises Better EBITDA Margins in FY27 vs FY26Oct 24, 2025
Laurus Labs has committed to delivering improved EBITDA margins in FY27 compared to FY26. The pharmaceutical company's promise indicates expectations for enhanced profitability in the upcoming fiscal year.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,685.90
#1 4,04,503.90
38.58
#1 54,729.00
9.71
#1 10,980
2.89
54.39
Divis Laboratories
6,883.50
1,82,735.30
79.27
9,712.00
18.67
2,191
26.74
74.24
Cipla
1,501.50
1,21,284.30
22.30
28,409.50
7.12
5,291
3.71
39.79
Torrent Pharmaceuticals
3,553.40
1,20,263.20
60.08
11,539.40
6.99
1,911
19.91
46.89
Dr Reddys Laboratories
1,205.20
1,00,587.70
#1 17.53
33,741.20
16.73
5,725
-0.38
36.98
Mankind Pharma
2,309.10
95,310.10
49.83
12,744.20
#1 20.90
2,007
-21.05
28.96
Zydus Life Science
936.70
94,253.90
20.00
23,511.00
18.55
4,615
34.60
30.29
Lupin
1,955.50
89,318.30
24.00
22,909.50
13.74
3,306
#1 72.75
50.08
Alkem Laboratories
5,643.50
67,476.50
28.92
13,458.30
3.70
2,216
21.39
62.15
Aurobindo Pharma
1,140.60
66,246.20
19.54
32,345.60
9.43
3,484
3.81
59.80
Growth Rate
Revenue Growth
11.09 %
Net Income Growth
110.70 %
Cash Flow Change
-9.62 %
ROE
88.26 %
ROCE
51.95 %
EBITDA Margin (Avg.)
26.61 %

Quarterly Financial Results

Quarterly Financials
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
412
525
519
483
486
545
489
565
542
599
531
637
555
714
732
841
981
1,144
1,295
1,417
1,284
1,206
1,034
1,426
1,541
1,577
1,546
1,383
1,185
1,226
1,197
1,458
1,197
1,228
1,425
1,779
1,580
1,680
Expenses
325
408
406
358
382
426
392
443
459
513
442
523
467
575
581
647
696
765
862
940
883
858
744
1,028
1,085
1,127
1,141
1,095
1,015
1,037
1,014
1,198
1,024
1,045
1,130
1,300
1,187
1,250
EBITDA
87
116
112
125
104
119
97
122
83
86
89
114
88
139
150
194
285
379
433
477
401
348
291
398
456
450
405
287
170
190
184
260
174
183
295
479
393
430
Operating Profit %
21 %
21 %
20 %
24 %
20 %
21 %
18 %
21 %
15 %
13 %
17 %
18 %
15 %
19 %
20 %
23 %
29 %
33 %
33 %
33 %
31 %
29 %
28 %
28 %
30 %
28 %
26 %
21 %
14 %
15 %
15 %
17 %
14 %
15 %
20 %
24 %
24 %
24 %
Depreciation
25
26
27
28
30
30
31
35
38
40
43
44
46
48
48
46
49
51
52
54
59
63
64
66
71
82
84
87
91
93
98
102
106
108
106
110
117
121
Interest
28
25
31
17
19
20
18
23
22
25
24
18
23
26
21
21
15
14
17
22
27
22
23
31
29
40
43
53
39
42
51
51
49
53
58
56
52
40
Profit Before Tax
35
66
54
81
55
70
49
64
23
22
23
53
19
66
82
127
222
314
364
401
316
263
204
302
356
328
278
147
41
54
35
107
19
23
131
312
224
270
Tax
9
18
9
9
16
21
14
19
6
6
5
9
4
9
8
17
50
72
91
104
74
59
49
70
104
95
75
42
14
17
11
32
6
3
38
80
63
75
Net Profit
26
48
45
71
39
49
35
45
17
16
18
43
15
57
74
110
172
242
273
297
242
204
155
232
252
233
203
105
27
37
23
75
13
20
93
233
162
195
EPS in ₹
3.73
5.18
4.50
6.75
3.68
4.61
3.29
4.26
1.56
1.53
1.67
4.07
1.42
1.06
1.38
2.06
3.21
4.53
5.09
5.53
4.50
3.76
2.87
4.29
4.68
4.33
3.78
1.90
0.46
0.69
0.43
1.40
0.23
0.37
1.71
4.34
3.02
3.61
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,894
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
Fixed Assets
801
1,021
1,230
1,481
1,629
1,726
2,171
2,653
3,409
3,890
4,123
Current Assets
865
1,003
1,140
1,248
1,463
1,812
3,075
3,345
3,462
3,835
4,332
Capital Work in Progress
110
70
143
163
110
67
362
813
551
423
458
Investments
0
7
3
3
3
3
3
31
50
124
233
Other Assets
983
1,126
1,277
1,369
1,589
1,953
3,215
3,472
3,651
3,950
4,521
Total Liabilities
1,894
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
Current Liabilities
805
884
1,121
1,307
1,424
1,692
2,457
2,681
2,432
3,112
3,540
Non Current Liabilities
365
483
202
227
349
288
693
928
1,180
1,159
1,193
Total Equity
724
857
1,330
1,483
1,558
1,770
2,601
3,359
4,049
4,116
4,603
Reserve & Surplus
642
774
1,225
1,371
1,447
1,658
2,490
3,244
3,930
4,003
4,365
Share Capital
82
82
106
106
106
107
107
108
108
108
108
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
24
-27
-10
1
0
-1
47
27
-30
93
-39
Investing Activities
-397
-312
-289
-384
-253
-221
-941
-915
-997
-822
-680
Operating Activities
-65
182
332
343
298
347
733
911
994
666
602
Financing Activities
486
103
-54
42
-45
-128
255
30
-27
250
39
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
27.45 %
27.30 %
27.30 %
27.27 %
27.27 %
27.27 %
27.27 %
27.20 %
27.20 %
27.20 %
27.20 %
27.19 %
27.19 %
27.18 %
27.18 %
27.62 %
27.62 %
27.59 %
27.59 %
FIIs
0.00 %
0.04 %
0.04 %
0.02 %
0.02 %
0.02 %
0.00 %
0.02 %
0.02 %
0.00 %
0.00 %
0.00 %
25.97 %
25.67 %
26.08 %
25.56 %
25.52 %
25.70 %
26.16 %
DIIs
2.06 %
2.40 %
2.11 %
2.77 %
3.51 %
4.77 %
8.98 %
9.51 %
9.74 %
10.14 %
10.71 %
10.77 %
11.77 %
13.56 %
13.05 %
12.74 %
11.77 %
11.94 %
11.73 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
34.17 %
34.18 %
32.91 %
32.87 %
31.15 %
28.42 %
27.96 %
28.95 %
28.49 %
28.26 %
26.49 %
25.01 %
23.95 %
22.68 %
22.67 %
22.72 %
23.65 %
23.12 %
23.33 %
Others
36.32 %
36.07 %
37.65 %
37.08 %
38.05 %
39.53 %
35.80 %
34.32 %
34.55 %
34.39 %
35.60 %
37.03 %
11.12 %
10.91 %
11.03 %
11.36 %
11.44 %
11.65 %
11.18 %
No of Share Holders
2,35,836
2,99,257
3,94,053
4,67,419
4,27,465
4,07,186
3,90,695
4,23,931
4,18,615
4,17,977
4,02,640
3,82,880
3,56,830
3,24,059
3,09,063
2,92,214
2,92,905
2,80,223
2,83,678

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 1.5 1.5 1.5 2.5 2 2 2 0.8 1.2
Dividend Yield (%) 0.00 1.49 1.88 2.31 0.69 0.34 0.67 0.51 0.13 0.12

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
09 Feb 2021 DIVIDEND Dividend
₹ 0.40 /share
 08 Feb 2021 366.20 356.95
12 May 2021 DIVIDEND Dividend
₹ 0.80 /share
 11 May 2021 474.45 491.75
18 Nov 2021 DIVIDEND Dividend
₹ 0.80 /share
 17 Nov 2021 574.90 484.00
11 May 2022 DIVIDEND Dividend
₹ 1.20 /share
 10 May 2022 578.80 525.10
04 Nov 2022 DIVIDEND Dividend
₹ 0.80 /share
 03 Nov 2022 526.20 477.75
10 May 2023 DIVIDEND Dividend
₹ 1.20 /share
 10 May 2023 300.05 334.30
02 Nov 2023 DIVIDEND Dividend
₹ 0.40 /share
 02 Nov 2023 396.40 358.90
08 May 2024 DIVIDEND Dividend
₹ 0.40 /share
 08 May 2024 434.40 429.45
11 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 11 Jul 2024 434.40 472.50
24 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 24 Oct 2024 480.30 449.35
06 Nov 2024 DIVIDEND Dividend
₹ 0.40 /share
 06 Nov 2024 449.35 489.25
24 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 24 Jan 2025 611.75 585.15
24 Apr 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 24 Apr 2025 564.25 650.45
09 May 2025 DIVIDEND Dividend
₹ 0.80 /share
 09 May 2025 650.45 586.00
26 Jun 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 26 Jun 2025 606.00 669.75
25 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 25 Jul 2025 778.30 836.50
23 Oct 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 23 Oct 2025 858.25 923.90
31 Oct 2025 DIVIDEND Dividend
₹ 0.80 /share
 31 Oct 2025 923.90 970.35

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication5 days ago
Announcement under Regulation 30 (LODR)-Earnings Call Transcript9 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 23, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationOct 23, 2025
Corporate Action-Board approves DividendOct 23, 2025
Board Meeting Outcome for Approval Of Unaudited Financial Statements For The Quarter And Half Year Ended September 30 2025 And Approval For Payment Of Interim Dividend For FY 2025-26Oct 23, 2025
Financial Results For The Quarter And Half Year Ended September 30 2025Oct 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 09, 2025
Board Meeting Intimation for Inter-Alia To Consider The Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025 And The Proposal For Payment Of Interim Dividend For FY 2025-26Oct 09, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Closure of Trading WindowSep 26, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationSep 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Scheme Of Arrangement Under Regulation 37(6) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementAug 21, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 30, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 29, 2025
Allotment Of 531.77 Acres Of Land By The Government Of Andhra PradeshJul 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 25, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 25, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJul 25, 2025
Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30 2025Jul 25, 2025
Unaudited Financial Results For The Quarter Ended 30.06.2025Jul 25, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 09, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended June 30 2025Jul 09, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 01, 2025
Closure of Trading WindowJun 27, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportJun 26, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMJun 26, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 12, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 09, 2025
Appointment Of Mr. Jyothi Basu Abbibeni As Executive Vice President - Chemical R&DJun 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 04, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jun 03, 2025
Reg. 34 (1) Annual Report.Jun 03, 2025
Notice Of The 20Th Annual General Meeting For The Financial Year 2024-25Jun 03, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 19, 2025
Board Meeting Outcome for Convening Of 20Th Annual General Meeting (AGM) Of The Company On Thursday June 26 2025 Through Video Conferencing/Other Audio Visual MeansMay 15, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 09, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptApr 28, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Mirae Asset Large & Midcap Fund Direct-Growth
0.00%
-5977891
-1.23%
-1.22%
SBI Large & Midcap Fund Direct Plan-Growth
0.00%
-5392600
-1.33%
-1.39%
Mirae Asset ELSS Tax Saver Fund Direct-Growth
0.00%
-4468387
-1.45%
-1.50%
Mirae Asset Midcap Fund Direct - Growth
0.00%
-2921215
-1.43%
-1.40%
DSP Healthcare Fund Direct - Growth
0.00%
-2217884
-6.07%
-6.12%
Axis Small Cap Fund Direct-Growth
0.00%
-2117487
-0.69%
-0.71%
Mahindra Manulife Multi Cap Fund Direct - Growth
0.00%
-2003815
-2.95%
-3.05%
SBI Healthcare Opportunities Fund Direct Plan-Growth
0.00%
-1400000
-3.00%
-3.03%
Kotak Arbitrage Fund Direct-Growth
0.00%
-1295400
-0.15%
-0.11%
DSP Equity Opportunities Fund Direct Plan-Growth
0.00%
-1017010
-0.54%
-0.57%
Mahindra Manulife Small Cap Fund Direct - Growth
0.00%
-952520
-1.97%
-2.05%
HDFC Pharma And Healthcare Fund Direct - Growth
0.00%
-806343
-3.58%
-3.62%
WhiteOak Capital Mid Cap Fund Direct - Growth
0.00%
-760659
-1.72%
-1.82%
Mirae Asset Healthcare Fund Direct - Growth
0.00%
-750748
-2.29%
-2.30%
DSP ELSS Tax Saver Fund Direct Plan-Growth
0.00%
-748841
-0.38%
-0.66%
Invesco India Arbitrage Fund Direct-Growth
0.00%
-700400
-0.22%
-0.18%
HDFC Innovation Fund Direct-Growth
0.00%
-696391
-2.26%
-2.37%
Tata Arbitrage Fund Direct - Growth
0.00%
-649400
-0.29%
-0.34%
Mahindra Manulife Large & Mid Cap Fund Direct - Growth
0.00%
-620000
-1.97%
-2.33%
Mirae Asset Aggressive Hybrid Fund Direct-Growth
0.00%
-569302
-0.53%
-0.54%
Aditya Birla Sun Life Quant Fund Direct-Growth
0.00%
-558978
-2.01%
-2.09%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-499917
-1.64%
-1.78%
ICICI Prudential Equity Arbitrage Direct-Growth
0.00%
-477700
-0.12%
-0.12%
Franklin India Mid Cap Fund Direct-Growth
0.00%
-472358
-0.33%
-0.33%
Axis Momentum Fund Direct - Growth
0.00%
-461472
-3.15%
0.00%

Technical Indicators

RSI(14)
Neutral
70.10
ATR(14)
Less Volatile
22.81
STOCH(9,6)
Overbought
89.65
STOCH RSI(14)
Overbought
87.04
MACD(12,26)
Bullish
6.22
ADX(14)
Weak Trend
24.29
UO(9)
Bearish
61.45
ROC(12)
Uptrend But Slowing Down
8.86
WillR(14)
Overbought
-12.06
Bearish
6
Neutral
2
Bullish
1

About Laurus Labs

Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company based in India. It operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis, and Ingredients. The company specializes in active pharmaceutical ingredients (APIs) for anti-retrovirals, Hepatitis C, and Oncology, among other therapeutic areas. Laurus Labs has four manufacturing facilities in Visakhapatnam, Andhra Pradesh, producing APIs, ingredients, and Finished Dosage Formulations (FDFs). The company serves global pharmaceutical markets, particularly in Sub-Saharan Africa, South-East Asia, and Latin America. Laurus Labs also offers contract development and manufacturing services, and produces specialty ingredients for the nutraceutical and cosmeceutical sectors. The company has expanded its operations through acquisitions, partnerships, and investments in new facilities and capabilities.
Listing Date
19 Dec, 2016(8 Years, 19 days)
Website
https://www.lauruslabs.com
Chairperson NameRavindranath Kancherla
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Technical Screeners
Fundamental Screeners
Intraday Screeners
Candlestick Screeners
Price & Volume Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104